NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Tim Noyes, CEO

Tim has 30 years’ industry experience leading all aspects of R&D and commercialization in the biopharmaceutical industry including Merck, Genzyme and Proteon. He has extensive launch planning and commercial launch experience. While at Genzyme, he headed all launch planning and the commercialization of Renagel, a treatment for hemodialysis patients that resulted in Genzyme’s acquisition of GelTex for more than $1 billion.